bluebird bio Blazes Trail for Lentiviral Vectors at Upcoming FDA Meeting

For the first time in half a decade, the U.S. Food and Drug Administration’s Cell, Tissue and Gene Therapies Advisory Committee will convene to address two therapies developed by bluebird bio in back-to-back meetings that will draw the eyes of all companies developing lentiviral vectors as potential therapeutics for rare diseases.